News

These conditions often result in organ failure due to myofibroblast activation, scarring, and tissue inflammation. Ono will work alongside Mediar to utilise its fibrosis-focused discovery platform, expertise in

This collaboration will focus on utilising Evotec’s data-driven discovery platform alongside its AI data science and advanced screening technologies. It aims to accelerate the discovery and validation of

The agreement involves access to ALT-B4 (berahyaluronidase alfa), a recombinant human hyaluronidase created with Alteogen’s Hybrozyme platform. This technology is intended to convert biologics typically given via intravenous

This initiative builds on an established partnership between the two companies, under which BMS already utilises Schrödinger’s computational platform for drug discovery projects. The new arrangement will extend

The funds will be used for AsymBio’s principal business operations and drive further expansion of its manufacturing capacity. Asymchem Group will contribute 1.05bn yuan while Hillhouse Qirui will

The move aims to address challenges in the sector where analytical work behind research decisions is often slow and dispersed, pushing scientists to use multiple disconnected tools and

The designation is specifically for patients whose tumours demonstrate a KRAS G12C mutation confirmed by an FDA-approved test and covers olomorasib administered as a monotherapy. Olomorasib (LY3537982) is

The deal will take the Nasdaq-listed Lantheus private. Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per share upon closing. Lantheus’ shareholders

The agreement covers the use of senaparib as a maintenance monotherapy for adult patients with advanced epithelial high-grade ovarian, fallopian tube, and primary peritoneal cancer. Under the agreement,